Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

NCT ID: NCT02345746

Last Updated: 2017-08-24

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-31
• Study Completion Date: 2013-12-31

Brief Summary

In this study, Hepatic Arterial Infusion will be combined with systemic therapy for patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy.

Detailed Description

In this phase II study, investigators will combine the HAI with systemic therapy for patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy. We hypothesize that combination therapy will be able to convert some patients to surgical resection candidates, or/and to overcome chemo-resistance of liver metastases to systemic i.v. chemotherapy for some clinically fit, heavily pre-treated patients

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Hepatic Artery Infusion

Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil

Group Type: EXPERIMENTAL

Oxaliplatin

Intervention Type: DRUG

infusion over 12 hours via HAI

Folinic Acid

Intervention Type: DRUG

as a 2-hour infusion via HAI on day 2

5-Fluorouracil

Intervention Type: DRUG

Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3

Interventions

Oxaliplatin

infusion over 12 hours via HAI

Intervention Type: DRUG

Folinic Acid

as a 2-hour infusion via HAI on day 2

Intervention Type: DRUG

5-Fluorouracil

Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3

Intervention Type: DRUG

Other Intervention Names

Eloxatin®; Leucovorin; 5-FU

Eligibility Criteria

Inclusion Criteria

1. Performance status ECOG 0-2 and a life expectancy of >3 months.

2. Patients were required to have measurable disease in the liver, defined as lesions measuring >1 cm in largest diameter on spiral-computed tomography (CT) or magnetic resonance imaging (MRI)

3. Histologically confirmed metastatic advanced solid tumors involving the liver, liver replacement less than 70%

4. No bevacizumab (avastin) use within 4 weeks prior to enrollment.

5. Absence of portal vein thrombosis

6. Not a surgical candidate or patients refuse surgery

7. Loss of response to at least two lines of systemic chemotherapy including FU, Oxaliplatin or irinotecan in metastatic setting

8. An asymptomatic extra-hepatic disease is allowed, provided that the extent of the metastatic disease in the liver represented the bulk of the metastatic disease.

9. History of liver-directed therapy is eligible at the investigator's discretion.

10. Adequate renal function with a calculated creatinine clearance greater than 60 mL/min.

11. Hepatic function as follows: Total Bilirubin ≤3 mg/dL, AST ≤5 times upper normal reference value, or ALT ≤ 5 times upper normal reference value.

12. Adequate bone marrow function (ANC ≥1500 cells/uL; PLT ≥ 100,000 cells/uL) before each therapy.

13. At least three weeks from previous immunotherapy, chemotherapy or radiotherapy before being enrolled in this study.

14. All females in childbearing age MUST have a negative serum HCG test unless patients have prior hysterectomy. Women of childbearing potential must take adequate precautions to prevent pregnancy during treatment.

15. Patient consent must be obtained prior to entrance onto study

Exclusion Criteria

1. Clinical or radiographic evidence of moderate amount of ascites.

2. History of cirrhosis with Child-Pugh class B or C.

3. Pregnant or lactating females.

4. Inability to complete informed consent process and adhere to protocol treatment plan and follow-up requirements.

5. Patients receiving any other investigational agents.

6. Patients with bleeding diathesis (clinical bleeding, prothrombin time =/> 1.5 X upper institutional normal value, INR =/> 1.5, activated partial thromboplastin time aPTT =/> 1.5 X upper institutional normal value), active gastric or duodenal ulcer.

7. History of thrombophilia, recurrent DVTs, diagnosis of phospholipid syndrome.

8. Past or current history of malignancy other than colon cancer with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS ≥5 years.

9. Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.

10. Patients with clinically significant cardiovascular disease: myocardial infarction or unstable angina within 6 months, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris, clinically significant peripheral vascular disease

11. Patients have untreated brain metastasis or leptomeningeal metastases requiring immediate intervention.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Western Regional Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Jordan Waypa

Research Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jiaxin Niu, MD

Role: PRINCIPAL_INVESTIGATOR

Western Regional Medical Center

Other Identifiers

12-19

Identifier Type: -

Identifier Source: org_study_id